By David A. Amato, DO, FAAD, Senior Medical Director, IQVIA Biotech
As the use of immunotherapies and biologics expand across dermatology indications, make sure you know the specific considerations for your clinical trial
As the science underpinning dermatological conditions has become more thoroughly understood, new therapeutic pathways have been identified and treatment options have rapidly evolved into biologic therapeutics and beyond. The first biologic approved for a dermatological indication was Amevive® for psoriasis in 2003. Today, there are more than 10 drugs on the market to treat psoriasis alone.1 Some biologics, such as dupilumab, have also been trialed for conditions outside of dermatology, such as asthma,2 eosinophilic esophagitis,3 and nasal polyposis.4
The global commercial dermatology market will continue to thrive, and is estimated to reach $33.7 billion by 2022, rising at a 7.73 percent compound annual growth rate from 2015 to 2022.7 With this momentum and the continued need for safe and effective dermatology treatments, it’s important to understand the strategic needs of clinical trials using novel immuno-dermatology agents.